Chemours (CC)
(Delayed Data from NYSE)
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Zacks News
Huntsman's Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
HUN's Q3 Polyurethanes sales increase is primarily driven by rising sales volumes, partly offset by reduced MDI prices.
Albemarle's Q3 Earnings and Sales Miss on Lower Lithium Pricing
by Zacks Equity Research
Lower lithium market prices weigh on ALB's Q3 results, partly masked by volume growth and cost and productivity benefits.
Air Products' Q4 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
The flat Q4 sales of APD are attributed to 1% increased volumes and pricing offset by 2% lower energy cost pass-through.
Cabot's Q4 Earnings and Revenues Miss Estimates, Rise Y/Y
by Zacks Equity Research
The decline in Q4 EBIT of CBT's Reinforcement Material segment is due to reduced volumes in the Americas, a less advantageous regional mix and higher costs.
Kronos Worldwide's Earnings Surpass Estimates in Q3, Sales Lag
by Zacks Equity Research
Higher sales volumes as a result of stronger demand for TiO2 in all major markets drive of KRO's top line in Q3.
Chemours' Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
CC sees record Q3 sales in the Thermal & Specialized Solutions division, driven by the growth in Opteon refrigerants.
Company News for Nov 5, 2024
by Zacks Equity Research
Companies in The News Are: CC,MAR,BAM,YUMC
Chemours (CC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemours (CC) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 25% and 5.32%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
LyondellBasell (LYB) Q3 Earnings Miss Estimates
by Zacks Equity Research
LyondellBasell (LYB) delivered earnings and revenue surprises of -7.39% and 0.49%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
DuPont de Nemours (DD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
DuPont de Nemours (DD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Chemours (CC) Q3 Earnings Expected to Decline
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dow Inc. (DOW) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Dow Inc. (DOW) delivered earnings and revenue surprises of 2.17% and 1.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Chemours Develops Low GWP Retrofit Approach for Vehicles
by Zacks Equity Research
CC anticipates its Opteon portfolio to save an estimated 325 million tons of carbon dioxide equivalent by 2025.
Chemours (CC) Opens Cutting-Edge Facility for EV Batteries
by Zacks Equity Research
Chemours (CC) opens the Chemours Battery Innovation Center to advance sustainable battery technology for electric vehicles.
Chemours (CC) Earnings Miss, Revenues Beat Estimates in Q2
by Zacks Equity Research
Chemours' (CC) earnings miss estimates in the second quarter due to lower selling prices.
Chemours (CC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemours (CC) Misses Q2 Earnings Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of -42.42% and 0.01%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Can These 4 Chemical Stocks Hit Targets This Earnings Season?
by Anindya Barman
Chemical companies are expected to have benefited from demand recovery across key end markets and moderated de-stocking activities. Let's see how APD, CE, CC and AXTA are poised ahead of their earnings releases.
Do Options Traders Know Something About Chemours (CC) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Analysts Estimate LyondellBasell (LYB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LyondellBasell (LYB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Chemours (CC) Q2 Earnings Expected to Decline
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours (CC) Soars 5.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Chemours (CC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Chemours (CC) Announces Enhancement of EVOLVE 2030 Methodology
by Zacks Equity Research
The revised EVOLVE 2030 approach improves Chemours' (CC) ability to integrate its business processes with this goal.
Why Is Chemours (CC) Down 2.1% Since Last Earnings Report?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.